Phase II, open-label study of erlotinib (ERL) in patients with NSCLC with activating mutations of the EGFR identified on tissue samples, plasma DNA, and CTC-trigger. This is an ASCO Meeting Abstract ...
CHENGDU, China--(BUSINESS WIRE)--Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results